NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Olema Pharmaceuticals, Inc. (OLMA) Stock Analysis

Olema Pharmaceuticals, Inc. (OLMA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

OLMA

$7.05

−$0.20 (−2.76%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OLMA with… →

OLMA Key Statistics

As of Oct 21, 2026
Trading
Open
$7.24
Previous Close
$7.25
Day's Range
7.03–7.47
52-Week Range
6.48–36.26
Volume
1.23M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.01
Valuation
Market Cap
$616.86M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.12
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$162.45M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
87.50M
1-Year Return
−14.86%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
1.11M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OLMA closed at $7.05, −14.86% over 1 year.

Olema Pharmaceuticals, Inc. (OLMA) has a market capitalization of $616.86M.

In fiscal 2025, OLMA reported revenue of $0.00.

OLMA Stock Return by Calendar Year

Olema Pharmaceuticals, Inc. (OLMA) return since Nov 2020: what $10,000 became

1 year
$10,000 $8,514
−14.86%
5 years
$10,000 $2,474
−75.26%
Since Nov 2020
$10,000 $1,439
−85.61%

If you had invested $10,000 in Olema Pharmaceuticals, Inc. (OLMA) at the close on November 19, 2020, the earliest close on record here, it would have been worth $1,439 at the close on October 21, 2026: −85.61% in total, −27.93% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.80%
2025+328.82%
2024−58.45%
2023+472.65%
2022−73.82%
2021−80.53%
2020 (partial year)−1.88%

As of October 21, 2026.

OLMA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$162.45M—
2024$0.00−$129.47M—
2023$0.00−$96.66M—
2022$0.00−$104.79M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$178.70M−$162.45M—
2024$0.00—−$142.26M−$129.47M—
2023$0.00—−$104.96M−$96.66M—
2022$0.00—−$106.99M−$104.79M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Olema Pharmaceuticals, Inc. (OLMA) at $616.86M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 150.

Over the past 52 weeks the price has ranged from $6.48 to $36.26. OLMA last closed at $7.05 on October 21, 2026. That is −$0.20 (−2.76%) against the previous close. The latest close sits 8.8% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $162.45M. Trailing earnings per share are −2.12.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −14.86%. Across 5 years the annualized return works out at −24.37%. Beta against the wider market is reported at 2.01. Daily returns over the trailing 5 years annualize to a volatility of 107.77%.

Growth & Income

No dividend is on file for OLMA.

2026 is still running; the total return is −71.80% year to date. Across the complete calendar years on file, 2023 returned +472.65% and 2021 returned −80.53%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Olema Pharmaceuticals, Inc. (OLMA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Olema Pharmaceuticals, Inc. OLMA $616.86M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Olema Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Visit website →